Aprea Therapeutics, Inc. (APRE)
NASDAQ: APRE · Real-Time Price · USD
0.6756
-0.0194 (-2.79%)
At close: Oct 5, 2026, 4:00 PM EDT
0.6900
+0.0144 (2.13%)
After-hours: Oct 5, 2026, 4:49 PM EDT
Aprea Therapeutics Revenue
Aprea Therapeutics had revenue of $5.19K in the twelve months ending June 30, 2026, down -99.38% year-over-year. In the year 2025, Aprea Therapeutics had annual revenue of $285.76K, down -80.98%.
Revenue (ttm)
$5.19K
Revenue Growth
-99.38%
P/S Ratio
1,606.61
Revenue / Employee
$648
Employees
8
Market Cap
8.51M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 285.76K | -1.22M | -80.98% |
| Dec 31, 2024 | 1.50M | 919.35K | 157.63% |
| Dec 31, 2023 | 583.23K | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Moolec Science | 7.83M |
| Immuron | 5.34M |
| Traws Pharma | 2.73M |
| Longeveron | 1.19M |
| Azitra | 7.50K |
| Soligenix | 2.34K |
APRE News
- 8 hours ago - Aprea Therapeutics to Present at October Conferences - GlobeNewsWire
- 13 days ago - Aprea Therapeutics to Present Updated Interim Phase 1 Data on WEE1 Inhibitor APR-1051 in an Oral Presentation at 38th EORTC-NCI-AACR Symposium - GlobeNewsWire
- 21 days ago - Aprea Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 25 days ago - Aprea Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewsWire
- 5 weeks ago - Aprea Therapeutics provides update on existing patent portfolio - TheFly
- 5 weeks ago - Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs - GlobeNewsWire
- 7 weeks ago - Aprea Therapeutics reports Q2 EPS (7c), consensus (22c) - TheFly
- 7 weeks ago - Aprea Therapeutics Announces Second Quarter 2026 Financial Results - GlobeNewsWire